Abstract:Epithelial splicing regulatory protein 2 (ESRP2),an important alternative splicing protein of mRNA, is reported to have a dual role in tumors, which can promote or inhibit the occurrence and development of tumors. However, the function and mechanism of ESRP2 in breast cancer (BC) remain unclear. The distribution of ESRP2 expression in breast cancer and the correlation between ESRP2 expression and the overall survival rate were detected by The Cancer Genome Atlas (TCGA) database. Gene Ontology(GO)analysis, containing biological process, cellular components, and molecular function, was utilized to evaluate the potential mechanism of ESRP2 in breast cancer. The ESRP2 expression in breast cancer cell lines was detected by real-time quantitative PCR analysis (RT-qPCR) and western blotting. Cell clone was performed to examine the proliferation of ESRP2 knockdown in MCF-7 cells. The cell cycle was measured by flow cytometry assays. The role of ESRP2 knockdown in synergistic effect with chemotherapeutic agents was also determined by MTT assay. Bioinformatics analysis demonstrated that the ESRP2 gene was elevated in breast cancer cells and its overexpression was strongly correlated with shorter overall survival. GO analysis revealed that ESRP2 expression was related to cell proliferation. ESRP2 mRNA and protein expression were elevated in breast cancer cell lines, compared to the normal human breast cell line MCF-10 A. Dwon-regulation of ESRP2 inhibited cell proliferation and promoted the sensitivity of chemotherapy drug, Cisplatin(DDP) and Paclitaxel (TAXOL), in MCF-7 cells.Additionally, ESRP2 knockdown obstructed the cell cycle at the G1 phase and caused a decrease in cyclinD1 protein expression. These findings reveal that ESRP2 is highly expressed in breast cancer and is correlated with poor prognosis in breast cancer patients. ESRP2 knockdown can inhibit MCF-7 cell proliferation by arresting the cell cycle at the G1 phase and promoting the sensitivity of chemotherapy drugs (DDP and TAXOL)in MCF-7 cells. ESRP2 may be required for the regulation of breast cancer progression, as well as a critical target for the clinical treatment of breast cancer.

Ehm2 Transcript Variant 1 Inhibits Breast Cancer Progression and Increases E-cadherin Stability.

Clinical Implications of the Influence of Ehm2 on the Aggressiveness of Breast Cancer Cells Through Regulation of Matrix Metalloproteinase-9 Expression.

Inhibitor of DNA Binding 2 Inhibits Epithelial-Mesenchymal Transition Via Up-Regulation of Notch3 in Breast Cancer

Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.

EHD2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Human Colon Cancer

EHD2 Inhibits the Invasive Ability of Lung Adenocarcinoma and Improves the Prognosis of Patients

Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma.

CTHRC1 Overexpression Promotes Ectopic Endometrial Stromal Cell Proliferation, Migration and Invasion Via Activation of the Wnt/β-catenin Pathway

EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma

EHD2 overexpression promotes tumorigenesis and metastasis in triple-negative breast cancer by regulating store-operated calcium entry

ERβ1 Inhibits the Migration and Invasion of Breast Cancer Cells Through Upregulation of E-cadherin in a Id1-dependent Manner.

MEF2D Functions as a Tumor Suppressor in Breast Cancer

HECW1 restrains cervical cancer cell growth by promoting DVL1 ubiquitination and downregulating the activation of Wnt/β-catenin signaling

The homeoprotein HOXB2 limits triple-negative breast carcinogenesis via extracellular matrix remodeling

A comprehensive analysis of different types of databases reveals that CDH1 mRNA and E-cadherin protein are not downregulated in most carcinoma tissues and carcinoma cell lines

Downregulation of UBAP2L Inhibits the Epithelial-Mesenchymal Transition Via SNAIL1 Regulation in Hepatocellular Carcinoma Cells

Embigin, Regulated by Hoxc8, Plays A Suppressive Role in Breast Tumorigenesis

Upregulation of HES1 Promotes Cell Proliferation and Invasion in Breast Cancer As a Prognosis Marker and Therapy Target Via the AKT Pathway and EMT Process

ERα Inhibits Epithelial-Mesenchymal Transition by Suppressing Bmi1 in Breast Cancer.

Id 2 Predicts Poor Prognosis in Breast Cancer , Especially in Triple-Negative Breast Cancer , and Inhibits E-Cadherin Expression

Down-regulation of ESRP2 inhibits breast cancer cell proliferation via inhibiting cyclinD1